Stockscreener 앱 받기
0.935
5.27%
0.0468
시간 외 거래:
.93
-0.005
-0.53%
전일 마감가:
$0.8882
열려 있는:
$0.8806
하루 거래량:
4.36M
Relative Volume:
1.50
시가총액:
$41.53M
수익:
-
순이익/손실:
$-51.50M
주가수익비율:
-0.2338
EPS:
-4
순현금흐름:
$-47.10M
1주 성능:
+9.84%
1개월 성능:
-53.25%
6개월 성능:
-37.67%
1년 성능:
-88.04%
1일 변동 폭
$0.86
$0.98
1주일 범위
$0.8194
$0.98
52주 변동 폭
$0.79
$8.32
아웃룩 테라퓨틱스 Stock (OTLK) Company Profile
명칭
Outlook Therapeutics Inc
전화
(609) 619-3990
주소
111 S. WOOD AVENUE, ISELIN, NJ
OTLK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
0.935 | 39.45M | 0 | -51.50M | -47.10M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
아웃룩 테라퓨틱스 Stock (OTLK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-08-28 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-12-02 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2024-03-27 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2024-02-15 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2024-01-25 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-12-27 | 업그레이드 | CapitalOne | Equal Weight → Overweight |
| 2023-08-31 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2023-08-31 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-08-30 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2023-08-30 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-08-30 | 다운그레이드 | CapitalOne | Overweight → Equal Weight |
| 2023-08-30 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-07-13 | 개시 | CapitalOne | Overweight |
| 2023-04-03 | 개시 | Guggenheim | Buy |
| 2023-02-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-10-31 | 개시 | BTIG Research | Buy |
| 2022-09-13 | 개시 | Chardan Capital Markets | Buy |
| 2019-09-11 | 개시 | Ladenburg Thalmann | Buy |
| 2019-05-16 | 개시 | Oppenheimer | Outperform |
| 2019-04-22 | 개시 | Ascendiant Capital Markets | Buy |
모두보기
아웃룩 테라퓨틱스 주식(OTLK)의 최신 뉴스
Price action breakdown for Outlook Therapeutics Inc.July 2025 Pullbacks & Verified Momentum Stock Watchlist - Newser
Trend analysis for Outlook Therapeutics Inc. this weekMarket Movement Recap & Expert Approved Momentum Ideas - Newser
Is Outlook Therapeutics Inc. stock trending bullishQuarterly Trade Review & Weekly Watchlist for Consistent Profits - خودرو بانک
Will Outlook Therapeutics Inc. benefit from macro trendsWeekly Stock Report & Daily Volume Surge Trade Alerts - Newser
Technical signs of recovery in Outlook Therapeutics Inc.July 2025 Closing Moves & Weekly Setup with ROI Potential - Newser
Analyzing Outlook Therapeutics Inc. with risk reward ratio chartsRisk Management & Fast Moving Market Watchlists - Newser
Can a trend reversal in Outlook Therapeutics Inc. lead to recoveryJuly 2025 Price Swings & Verified Momentum Stock Watchlist - Newser
Real time breakdown of Outlook Therapeutics Inc. stock performanceJuly 2025 Pullbacks & Weekly High Potential Stock Alerts - Newser
Does Outlook Therapeutics Inc. have pricing power2025 Biggest Moves & Low Drawdown Trading Techniques - khodrobank.com
Largest borrow rate increases among liquid names - TipRanks
Is Outlook Therapeutics Inc.’s ROE strong enough2025 Volume Leaders & Technical Buy Zone Confirmation - خودرو بانک
What Fibonacci levels say about Outlook Therapeutics Inc. reboundJuly 2025 Gainers & Expert Approved Momentum Trade Ideas - Newser
Is Outlook Therapeutics Inc. showing insider buyingPortfolio Risk Report & Consistent Profit Alerts - خودرو بانک
How to build a custom watchlist for Outlook Therapeutics Inc.2025 Market Sentiment & Weekly Stock Breakout Alerts - Newser
Outlook Therapeutics shares fall 1.61% intraday after requesting a meeting with the US FDA. - AInvest
Will Outlook Therapeutics Inc. continue its uptrendJuly 2025 Market Mood & Proven Capital Preservation Methods - Newser
Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS) - GlobeNewswire
Outlook Therapeutics to Present at EURETINA Innovation Spotlight - AInvest
Will Outlook Therapeutics Inc. benefit from seasonalityOil Prices & Free Verified High Yield Trade Plans - خودرو بانک
Long term hold vs stop loss in Outlook Therapeutics Inc.Market Trend Report & AI Driven Price Forecasts - Newser
Using economic indicators to assess Outlook Therapeutics Inc. potential2025 Breakouts & Breakdowns & Risk Managed Investment Strategies - Newser
Is Outlook Therapeutics Inc. showing signs of accumulationAnalyst Upgrade & AI Based Buy and Sell Signals - Newser
Quantitative breakdown of Outlook Therapeutics Inc. recent moveTrade Signal Summary & Short-Term High Return Strategies - Newser
Tools to assess Outlook Therapeutics Inc.’s risk profileVolume Spike & Community Trade Idea Sharing - Newser
How to track smart money flows in Outlook Therapeutics Inc.July 2025 Sector Moves & Consistent Profit Trade Alerts - Newser
Will Outlook Therapeutics Inc. bounce back from current supportAnalyst Downgrade & Risk Controlled Daily Plans - Newser
Evaluating Outlook Therapeutics Inc. with trendline analysisWeekly Loss Report & Daily Momentum Trading Reports - Newser
Strategies to average down on Outlook Therapeutics Inc.Trade Signal Summary & Consistent Return Strategy Ideas - Newser
Is Outlook Therapeutics Inc. part of any ETF2025 Volume Leaders & Stepwise Entry and Exit Trade Signals - خودرو بانک
Published on: 2025-09-02 23:49:13 - Newser
Is Outlook Therapeutics Inc. meeting your algorithmic filter criteria2025 Breakouts & Breakdowns & Smart Allocation Stock Tips - Newser
US FDA Emphasizes Primary Endpoint Primacy In Vatiquinone, Lytenava CRLs - insights.citeline.com
Outlook Therapeutics provides regulatory update on FDA review of ONS-5010/LYTENAVA (bevacizumab-vikg) for the treatment of wet AMD - Eyes On Eyecare
Outlook Therapeutics receives second FDA CRL over wet AMD BLA - Eyes On Eyecare
Outlook Therapeutics Requests Meeting With US FDA Regarding Complete Response Letter for ONS-5010 - MarketScreener
Outlook Therapeutics’ Path to FDA Clarity and Commercialization of ONS-5010: Strategic and Financial Implications for Biotech Investors - AInvest
Outlook Therapeutics requests Type A meeting with FDA - MarketScreener
Outlook Therapeutics shares rise 1.65% intraday after requesting a Type A meeting with the FDA to discuss ONS-5010. - AInvest
Tools to assess Vanda Pharmaceuticals Inc.’s risk profile2025 Market Outlook & Verified Swing Trading Watchlist - Newser
Outlook Therapeutics Requests Type A Meeting with FDA - The Manila Times
Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS-5010 Biologics License Application - Quiver Quantitative
Outlook Therapeutics Submits Type A Meeting Request to FDA. - AInvest
FDA Requests Additional Efficacy Data: Outlook Therapeutics Plans Meeting on Wet-AMD Drug ONS-5010 - Stock Titan
Outlook Therapeutics Inc. stock volume spike explained2025 Price Action Summary & Verified Momentum Stock Ideas - Newser
Outlook Therapeutics Reports Q3 Revenue - AOL.com
Wesson Brands Inc. stock outlook for YEAR2025 Biggest Moves & Daily Stock Trend Watchlist - Newser
아웃룩 테라퓨틱스 (OTLK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.40%
자본화:
|
볼륨(24시간):